NCT01151319

Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults

A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: University of Oxford · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.

Conditions

• HIV-1 Infections

Interventions

Type	Name	Description
BIOLOGICAL	ChAdV63.HIVconsv low dose.	Attenuated chimp adenovirus. 5x10\^9 virus particles.
BIOLOGICAL	ChAdV63.HIVconsv high dose.	Attenuated chimp adenovirus at 5x10\^10 virus particles.
BIOLOGICAL	pSG2.HIVconsv	DNA at 4mg per dose.
BIOLOGICAL	MVA.HIVconsv	Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
OTHER	Placebo	Phosphate buffered saline

Timeline

• Start date: 2010-10-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2010-06-28
• Last updated: 2014-04-30

Locations

1 site across 1 country: United Kingdom